IVBXF
Price:
$4.5682
Market Cap:
$7.47B
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarci...[Read more]
Industry
Biotechnology
IPO Date
2019-09-04
Stock Exchange
PNK
Ticker
IVBXF
According to Innovent Biologics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 8.35B. This represents a change of -78.21% compared to the average of 38.30B of the last 4 quarters.
The mean historical Enterprise Value of Innovent Biologics, Inc. over the last ten years is 40.88B. The current 8.35B Enterprise Value has changed 1.94% with respect to the historical average. Over the past ten years (40 quarters), IVBXF's Enterprise Value was at its highest in in the June 2021 quarter at 108.82B. The Enterprise Value was at its lowest in in the March 2021 quarter at -9322770000.00.
Average
40.88B
Median
36.28B
Minimum
3.53B
Maximum
90.69B
Discovering the peaks and valleys of Innovent Biologics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 646.49%
Maximum Annual Enterprise Value = 90.69B
Minimum Annual Increase = -84.64%
Minimum Annual Enterprise Value = 3.53B
Year | Enterprise Value | Change |
---|---|---|
2023 | 55.34B | 19.64% |
2022 | 46.25B | -20.26% |
2021 | 58.00B | -36.04% |
2020 | 90.69B | 244.63% |
2019 | 26.31B | 646.49% |
2018 | 3.53B | -84.64% |
2017 | 22.95B | -4.29% |
The current Enterprise Value of Innovent Biologics, Inc. (IVBXF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
53.20B
5-year avg
55.32B
10-year avg
40.88B
Innovent Biologics, Inc.’s Enterprise Value is greater than Telix Pharmaceuticals Limited (6.70B), greater than Keros Therapeutics, Inc. (1.86B), greater than MAIA Biotechnology, Inc. (57.27M), greater than Graphite Bio, Inc. (-15007658.00), less than Genscript Biotech Corporation (0), greater than Oxford Nanopore Technologies plc (3.70B), greater than Nuvalent, Inc. (1.20B), greater than Crinetics Pharmaceuticals, Inc. (6.17B), greater than Inhibrx Biosciences, Inc. (4.87B), greater than Merus N.V. (411.31K), greater than Lyell Immunopharma, Inc. (3.08B), greater than Kronos Bio, Inc. (251.92M), greater than Theseus Pharmaceuticals, Inc. (14.20M), greater than Cullinan Oncology, Inc. (138.26M), greater than Mersana Therapeutics, Inc. (810.70M), greater than Relay Therapeutics, Inc. (199.03M), greater than Arcus Biosciences, Inc. (867.37M), greater than null (1.28B),
Company | Enterprise Value | Market cap |
---|---|---|
6.70B | $4.48B | |
1.86B | $2.25B | |
57.27M | $68.85M | |
-15007658.00 | $185.19M | |
0 | $3.22B | |
3.70B | $1.70B | |
1.20B | $6.25B | |
6.17B | $5.12B | |
4.87B | $225.10M | |
411.31K | $3.51B | |
3.08B | $325.12M | |
251.92M | $57.28M | |
14.20M | $181.50M | |
138.26M | $922.99M | |
810.70M | $225.72M | |
199.03M | $950.40M | |
867.37M | $1.42B | |
1.28B | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innovent Biologics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innovent Biologics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Innovent Biologics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Innovent Biologics, Inc. (IVBXF)?
What is the 3-year average Enterprise Value for Innovent Biologics, Inc. (IVBXF)?
What is the 5-year average Enterprise Value for Innovent Biologics, Inc. (IVBXF)?
How does the current Enterprise Value for Innovent Biologics, Inc. (IVBXF) compare to its historical average?